2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexene-1-carboxaldehyde

We are 2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexene-1-carboxaldehyde CAS:1228837-05-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexene-1-carboxaldehyde
CAS.NO:  1228837-05-5
Synonyms:1-Cyclohexene-1-carboxaldehyde, 2-(4-chlorophenyl)-4,4-dimethyl-
2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexene-1-carbaldehyde

Molecular Formula: C15H17ClO
Molecular Weight:248.74800

Physical and Chemical Properties:
Density: 1.1±0.1 g/cm3
Boiling point: 347.9±42.0 °C at 760 mmHg
Melting point: /
Flash point: 206.8±19.0 °C
Refractive index: 1.584

Specification:
Appearance:White to off-white powder
Purity:≥98.0%
Single impunity:≤0.15%
Other impunity:≤0.1%
Water content(KF):0.50%(max.)

Packing:
 25kg 1 cardboard drum or according to customer specified requirements
Storage:Shade light and keep tightly closed.
Application: Intermediates of ABT-199 CAS:1257044-40-8.

Related News: The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution.2-chloro-1-fluoro-4-isothiocyanatobenzene CAS:137724-66-4 The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution.Ácido 3-bromo-2-fluorobenzoico CAS:161957-56-8 Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.HC Yellow 7 CAS:104226-21-3 Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.